{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:25:00Z","timestamp":1780586700328,"version":"3.54.1"},"reference-count":227,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2019,5,24]]},"DOI":"10.1080\/14656566.2019.1584182","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T22:05:12Z","timestamp":1552082712000},"page":"1009-1024","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["New and emerging drugs for the treatment of acne vulgaris in adolescents"],"prefix":"10.1080","volume":"20","author":[{"given":"Isabel Cristina","family":"Valente Duarte De Sousa","sequence":"first","affiliation":[{"name":"Department of Dermatology, ABC Hospital, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,3,8]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13675"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.078"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000649"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.618"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04346.x"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1159\/000067817"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.47"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12149"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0490B"},{"issue":"2","key":"CIT0010","first-page":"4","volume":"76","author":"Webster GF","year":"2005","journal-title":"Cutis"},{"issue":"12","key":"CIT0011","first-page":"892","volume":"46","author":"Gebauer K","year":"2017","journal-title":"Aust Fam Physician"},{"issue":"2","key":"CIT0012","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/ijd.IJD_671_16","volume":"63","author":"Eyuboglu M","year":"2018","journal-title":"Indian J Dermatol"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2017.10.004"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12708"},{"issue":"1","key":"CIT0015","first-page":"1","volume":"17","author":"Dunn LK","year":"2011","journal-title":"Dermatol Online J"},{"issue":"2","key":"CIT0016","first-page":"97","volume":"16","author":"Tan J","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1099\/ijsem.0.001367"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.01.019"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13776"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"issue":"2","key":"CIT0021","first-page":"S1","volume":"8","author":"Nast A","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15843"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.12.031"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700434"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03531.x"},{"key":"CIT0026","first-page":"1927","volume-title":"Textbook of dermatology","author":"Cunliffe WJ","year":"1998","edition":"6"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09878.x"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10332.x"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-012-1265-x"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2001.01312.x"},{"key":"CIT0031","unstructured":"Kelce W Topical nitric oxide: a first-in-class local antiandrogen therapy for the treatment of acne and male pattern baldness. (White Paper). Novan Therapeutics. [cited 2018 Oct 30]. Available from: http:\/\/www.novan.com\/files\/8613\/7398\/9326\/Topical_nitric_oxide_local_androgen_therapy.pdf"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1159\/000246242"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.4161\/derm.1.2.8354"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.225"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.00613.x"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2013.02.006"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12261491"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2008.06.002"},{"issue":"12","key":"CIT0039","first-page":"881","volume":"54","author":"Celasco G","year":"2004","journal-title":"Arzneimittelforschung"},{"key":"CIT0040","unstructured":"An evaluation of the adrenal suppression potential and pharmacokinetic properties of CB-03-01 crema in subjects with acne: Identifier NCT01831960 Clinical Trials: A service of the U.S. National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0041","unstructured":"A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris: Identifier: NCT01631474. Clinical Trials: A service of the U.S. National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0042","unstructured":"An evaluation of the adrenal suppression potential and pk of cb-03-01 cream in pediatric patients with acne vulgaris: Identifier NCT02720627. Clinical Trials: A service of the U.S. National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0043","unstructured":"A study to evaluate the safety and efficacy of cb-03-01 cream, 1% in subjects with facial acne vulgaris: Identifier NCT02608476 Clinical Trials: A service of the U.S. National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0044","unstructured":"A study to evaluate the safety and efficacy of cb-03-01 cream, 1% in subjects with facial acne vulgaris: Identifier NCT02608450. Clinical Trials: A service of the U.S. National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1038\/nm1547"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39335"},{"key":"CIT0047","unstructured":"A phase 2 study of ASC-J9 cream in acne vulgaris. Identifier NCT00525499. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0048","unstructured":"Topical ASC-J9 cream for acne: Identifier NCT01289574. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2003.00014.x"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00246.x"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nutr.17.1.77"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.9.2.267"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-005-5121-4"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.01.026"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S69135"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1997.00001.x"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.053"},{"key":"CIT0058","unstructured":"A safety, tolerability and preliminary efficacy study of DRM01B topical gel: Identifier NCT01936324 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0059","unstructured":"A dose-ranging study of DRM01 in subjects with acne vulgaris: Identifier: NCT02431052 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0060","unstructured":"A study of olumacostat glasaretil gel in subjects with acne vulgaris: Identifier: NCT03073486 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0061","unstructured":"A study of olumacostat glasaretil gel in subjects with acne vulgaris: Identifier NCT03028363 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0062","unstructured":"A long-term safety study of olumacostat glasaretil gel in subjects with acne vulgaris: Identifier: NCT03127956 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"issue":"6","key":"CIT0063","first-page":"AB184","volume":"76","author":"Del Rosso JQ","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-139-8-1745"},{"issue":"5","key":"CIT0065","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/JCM.12.5.672-675.1980","volume":"12","author":"McGinley KJ","year":"1980","journal-title":"J Clin Microbiol"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.0640503"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00094.x"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2003.tb03175.x"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2011.04.001"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2005.05.030"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.10.100"},{"key":"CIT0072","unstructured":"A multi-center, double-blind, vehicle controlled, phase ii study of JNJ 10229570-AAA for the treatment of acne vulgaris. Identifier: NCT01326780 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700278"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701155"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041370210"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12469799"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041510207"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1210\/endo.134.1.8275938"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1136\/mp.54.3.133"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.26.7.2675-2687.2006"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00924.x"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-005-0715-8"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00890.x"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1995.tb03381.x"},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.3.333"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08764.x"},{"key":"CIT0087","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.281"},{"key":"CIT0088","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.202"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.292"},{"issue":"4","key":"CIT0090","first-page":"369","volume":"7","author":"Liao S","year":"2001","journal-title":"Hong Kong Med J"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2010.2697"},{"issue":"4","key":"CIT0092","first-page":"358","volume":"8","author":"Elsaie ML","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"CIT0093","unstructured":"Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes: Identifier\u2028NCT01687556. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0094","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.29"},{"key":"CIT0095","unstructured":"Clinical study for the effectiveness and safety of topical lupeol in mild to moderate acne: Identifier: NCT02205892 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0096","unstructured":"Clinical trial of lupeol for mild-moderate acne: Identifier NCT02152865 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0097","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64628"},{"key":"CIT0098","unstructured":"A randomized, double-blind, vehicle-controlled study to evaluate the safety and efficacy of BTX-1503 in patients with moderate to severe acne vulgaris: Identifier NCT03573518 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0099","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0185-2"},{"issue":"32","key":"CIT0100","doi-asserted-by":"crossref","first-page":"20629","DOI":"10.1016\/S0021-9258(17)32039-2","volume":"269","author":"Fisher GJ","year":"1994","journal-title":"J Biol Chem"},{"key":"CIT0101","doi-asserted-by":"publisher","DOI":"10.1038\/332850a0"},{"key":"CIT0102","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-58483-1_6"},{"key":"CIT0103","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.10.9.8801176"},{"issue":"8","key":"CIT0104","first-page":"49","volume":"10","author":"Endly DC","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"CIT0105","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1242\/jcs.102.1.113","volume":"102","author":"Redfern CP","year":"1992","journal-title":"J Cell Sci"},{"key":"CIT0106","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.04.036"},{"issue":"2","key":"CIT0107","first-page":"442","volume":"179","author":"Aubert J","year":"2018","journal-title":"Br J Dermatol"},{"key":"CIT0108","unstructured":"A randomized, multi-center, investigator-blind, vehicle- and active-controlled, phase 2 study to assess the efficacy and safety of different concentrations of CD5789 cream applied once daily in subjects with moderate to severe acne vulgaris: Identifier: NCT01616654 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0109","unstructured":"A long-term safety and efficacy study of CD5789 (trifarotene) 50 \u00b5g\/g cream in subjects with acne vulgaris: Identifier NCT02189629 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0110","unstructured":"A multi-center, randomized, double-blind, parallel-group vehicle controlled study to compare the efficacy and safety of CD5789 (trifarotene) 50\u00b5g\/g cream versus vehicle cream in subjects with acne vulgaris: Identifier NCT02556788 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0111","unstructured":"A multi-center, randomized, double-blind, parallel-group vehicle controlled study to compare the efficacy and safety of CD5789 (trifarotene) 50\u00b5g\/g cream versus vehicle cream in subjects with acne vulgaris: Identifier NCT02566369 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0112","doi-asserted-by":"publisher","DOI":"10.1053\/sder.2001.28207"},{"issue":"1","key":"CIT0113","first-page":"11766","volume":"8","author":"Cebrian R","year":"2018","journal-title":"SciRep"},{"key":"CIT0114","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12321.x"},{"issue":"6","key":"CIT0115","first-page":"582","volume":"6","author":"Rosen T","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"CIT0116","doi-asserted-by":"publisher","DOI":"10.1126\/science.1100330"},{"key":"CIT0117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2009.02.015"},{"key":"CIT0118","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2009.03.012"},{"key":"CIT0119","first-page":"109","volume":"12","author":"Del Rosso JQ","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"CIT0120","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-961811"},{"key":"CIT0121","doi-asserted-by":"publisher","DOI":"10.4161\/derm.1.2.8102"},{"key":"CIT0122","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12607634"},{"key":"CIT0123","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15043"},{"key":"CIT0124","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15042"},{"key":"CIT0125","doi-asserted-by":"publisher","DOI":"10.1038\/srep39491"},{"key":"CIT0126","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14967"},{"key":"CIT0127","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.3.409"},{"key":"CIT0128","doi-asserted-by":"publisher","DOI":"10.1159\/000067822"},{"key":"CIT0129","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05067.x"},{"key":"CIT0130","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2016.10.008"},{"key":"CIT0131","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04690.x"},{"key":"CIT0132","unstructured":"A randomized, multicenter, double-blind, placebo-controlledsStudy to evaluate the efficacy and safety of 1.5 mg\/kg per day of sarecycline compared to placebo in the treatment of acne vulgaris: Identifier: NCT02320149 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0133","unstructured":"A multi-center open-label evaluation of the safety of sarecycline tablets in the Treatment of acne vulgaris: Identifier: NCT02413346 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0134","unstructured":"A randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of 1.5 mg\/kg per day of sarecycline compared to placebo in the treatment of acne vulgaris: Identifier NCT02322866 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0135","doi-asserted-by":"publisher","DOI":"10.1016\/S0142-9612(03)00173-X"},{"key":"CIT0136","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2003.01588.x"},{"key":"CIT0137","doi-asserted-by":"publisher","DOI":"10.1016\/j.resmic.2007.02.001"},{"key":"CIT0138","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2478(90)90083-3"},{"issue":"2","key":"CIT0139","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/IAI.61.2.689-698.1993","volume":"61","author":"Green SJ","year":"1993","journal-title":"Infect Immun"},{"key":"CIT0140","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.277"},{"key":"CIT0141","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1307"},{"key":"CIT0142","doi-asserted-by":"publisher","DOI":"10.1210\/endo.137.12.8940355"},{"key":"CIT0143","doi-asserted-by":"publisher","DOI":"10.1210\/endo.139.3.5773"},{"key":"CIT0144","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(02)00214-9"},{"key":"CIT0145","unstructured":"A phase 1, single-center, open-label pharmacokinetic, safety and tolerability study of SB204 in adolescents with moderate to severe acne vulgaris: NCT02801903 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0146","unstructured":"A phase 2, multi-center, randomized, evaluator-blinded, vehicle-controlled study comparing the efficacy, tolerability, and safety of SB204 gel and vehicle gel once or twice daily in the treatment of acne vulgaris: Identifier NCT02242760 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30].Available from: www.clinicaltrials.gov"},{"issue":"8","key":"CIT0147","first-page":"12","volume":"9","author":"Baldwin H","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"issue":"12","key":"CIT0148","first-page":"1496","volume":"15","author":"Eichenfield LF","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"CIT0149","unstructured":"A phase 3 multi-center, open label study evaluating the long term safety of SB204 once daily in the treatment of acne vulgaris: Identifier NCT02798120 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0150","unstructured":"A phase 3 multi-center, randomized, double-blinded, vehicle-controlled, parallel group study comparing the efficacy, tolerability and safety of SB204 and vehicle gel once daily in the treatment of acne vulgaris: Identifier: NCT02672332 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0151","unstructured":"A phase 3 multi-center, randomized, double-blinded, vehicle-controlled, parallel group study comparing the efficacy, tolerability and safety of SB204 and vehicle gel once daily in the treatment of acne vulgaris: Identifier: NCT02667444 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0152","unstructured":"A multicenter, randomized, double-blind, vehicle-controlled, parallel group comparison study to evaluate the safety and efficacy of UHE-101 cream 1% when applied twice daily for 12 weeks in subjects with facial acne vulgaris: Identifier NCT03307577 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0153","unstructured":"AAPPTEC. Safety Data Sheet. [cited 2018 Oct 30]. Available at: https:\/\/www.peptide.com\/msds\/MSDS%20UHE101%20H-beta-HGlu%20HCl.pdf"},{"key":"CIT0154","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12159"},{"key":"CIT0155","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2009.08.002"},{"key":"CIT0156","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2937"},{"key":"CIT0157","doi-asserted-by":"publisher","DOI":"10.2174\/138920111796117364"},{"key":"CIT0158","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2011.573478"},{"key":"CIT0159","doi-asserted-by":"publisher","DOI":"10.1111\/jam.13033"},{"key":"CIT0160","doi-asserted-by":"publisher","DOI":"10.2174\/157489106777452638"},{"key":"CIT0161","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.2006.00156.x"},{"key":"CIT0162","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2009.02.006"},{"key":"CIT0163","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3112-3118.2004"},{"key":"CIT0164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.05.003"},{"key":"CIT0165","unstructured":"A phase 2, randomized, double-blind, vehicle-controlled, parallel group multicenter study to evaluate the safety and efficacy of CLS001 topical gel versus vehicle applied once daily for 12 weeks to female subjects with moderate to severe acne vulgaris: Identifier NCT02571998 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0166","unstructured":"A phase ii, randomized, vehicle-controlled, double-blind, multi-center study to evaluate safety and efficacy of MBI 226 1.25% and 2.5% acne solutions applied topically for 12 weeks to subjects with acne vulgaris: Identifier NCT00211497 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0167","unstructured":"A phase 2, randomized, vehicle-controlled, double-blind, multicenter study to evaluate the safety and efficacy of three once-daily CLS001 topical gels versus vehicle administered for 12 weeks to subjects with acne vulgaris: Identifier NCT02066545 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0168","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001053"},{"key":"CIT0169","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2013.10.065"},{"key":"CIT0170","unstructured":"Borunda JSA, Castro JARM, Santoyo PP, et al. Semi- solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne. Google Patents. 2016. [cited 2018 Oct 15]. Available from: https:\/\/patents.google.com\/patent\/US20160228424A1\/en"},{"key":"CIT0171","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12625"},{"key":"CIT0172","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2016-0217OC"},{"key":"CIT0173","unstructured":"Molecular and clinical study of the effect of zaxcell versus effezel in the inflammatory and scarring process of moderate and severe acne: Identifier NCT03076320. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0174","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2006.04.001"},{"key":"CIT0175","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23705.x"},{"key":"CIT0176","unstructured":"Studie van de huidmicrobiota en het potentieel van een cr\u00e8me met probiotica bij personen met acne: Identifier NCT03469076 Clinical Trials: A service of the U.S. National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0177","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1337745"},{"issue":"6","key":"CIT0178","first-page":"677","volume":"15","author":"Bernhardt MJ","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"CIT0179","unstructured":"Next Science develops biofilm-fighting acne treatment gel-NextScience. [cited 2018 Oct 15]. Available from: https:\/\/www.nextscience.com\/2016\/05\/01\/next-science-develops-biofilm-fighting-acne-treatment-gel\/"},{"key":"CIT0180","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13579"},{"key":"CIT0181","unstructured":"A multi-center, double-blind, vehicle-controlled study to evaluate the clinical effect of daily Next Science\u2122 Acne gel (NAG) on mild to moderate facial acne: Identifier: NCT02404285 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0182","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-43493"},{"key":"CIT0183","unstructured":"Acebilustat (CTX-4430). CFF Clinical Trial Tools. [cited 2018 Oct 18]. Available from: https:\/\/www.cff.org\/Trials\/Pipeline\/details\/108\/Acebilustat-CTX-4430"},{"key":"CIT0184","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12426"},{"key":"CIT0185","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-005-0715-8"},{"key":"CIT0186","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00929.x"},{"key":"CIT0187","unstructured":"A multi-centre, double-blind, randomized, parallel group, placebo controlled efficacy and safety study of oral CTX-4430 for the treatment of moderate to severe facial acne vulgaris: Identifier: NCT02385760 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0188","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.1.13989"},{"key":"CIT0189","first-page":"w13590","volume":"142","author":"Contassot E","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"CIT0190","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-010-0109-z"},{"key":"CIT0191","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12035"},{"key":"CIT0192","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.438"},{"key":"CIT0193","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.309"},{"key":"CIT0194","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2219"},{"key":"CIT0195","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22976"},{"key":"CIT0196","unstructured":"A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of gevokizumab in subjects with moderate to severe acne vulgaris Identifier NCT01498874. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0197","unstructured":"XOMA announces encouraging interim result from gevokizumab phase 2 study for moderate to severe acne vulgaris-Aktuell-Servier (Suisse) S.A. Conversum, Preterax, Fludex,Diamicron, Locabiotal, Arcalion, Daflon. [cited 2018 Oct 30]. Accessed from: https:\/\/www.servier.ch\/de\/aktuell\/news-detail\/2\/xoma-announces-encouraging-interim-results-from-gevokizumab-phase-2-study-for-moderate-to-severe-acne-vulgaris\/"},{"key":"CIT0198","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12481"},{"key":"CIT0199","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2009.08.001"},{"issue":"1","key":"CIT0200","first-page":"5","volume":"77","author":"Fivenson DP","year":"2006","journal-title":"Cutis"},{"key":"CIT0201","doi-asserted-by":"publisher","DOI":"10.1159\/000359974"},{"key":"CIT0202","doi-asserted-by":"publisher","DOI":"10.1080\/14764170600717704"},{"key":"CIT0203","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1995.tb04449.x"},{"key":"CIT0204","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12002"},{"key":"CIT0205","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2494.2011.00658.x"},{"key":"CIT0206","unstructured":"Efficacy and tolerability of nicotinamide plus cream for moderate acne vulgaris in indonesia: a multicenter clinical trial: Identifier NCT03626298. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0207","unstructured":"Sodium 3-[ethyl(3-methoxyphenyl)amino]-1-propanesulfonate. C12H18NNaO4S. ChemSpider. [cited 2018 Oct 30]. Accesed from: http:\/\/www.chemspider.com\/Chemical-Structure.8119613.html?rid=6e6abbbd-1231-4cf5-a2b7-7ffa487b2fcf&page_num=0"},{"key":"CIT0208","unstructured":"A multi-center, double-blind, randomized, placebo controlled, parallel-group study to evaluate the efficacy and safety of ADPS in the treatment of acne vulgaris: Identifier: NCT02935036 Clinical Trial: Identifier NCT03626298. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov"},{"key":"CIT0209","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0178-4"},{"key":"CIT0210","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14026"},{"key":"CIT0211","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1309349"},{"key":"CIT0212","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2007.00552.x"},{"issue":"6","key":"CIT0213","first-page":"611","volume":"12","author":"Eichenfield LF","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"CIT0214","first-page":"313","volume":"11","author":"Zeichner JA","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"CIT0215","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1684\/ejd.2014.2309","volume":"24","author":"Dreno B","year":"2014","journal-title":"Eur J dermatol"},{"key":"CIT0216","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06614.x"},{"key":"CIT0217","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2008.06.001"},{"key":"CIT0218","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60321-8"},{"key":"CIT0219","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70177-4"},{"key":"CIT0220","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.5254"},{"issue":"2","key":"CIT0221","first-page":"103","volume":"86","author":"Yentzer BA","year":"2010","journal-title":"Cutis"},{"key":"CIT0222","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e328305e273"},{"issue":"3","key":"CIT0223","first-page":"264","volume":"17","author":"Del Rosso JQ","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"CIT0224","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0352-y"},{"key":"CIT0225","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.1297"},{"key":"CIT0226","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13325"},{"key":"CIT0227","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000392"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2019.1584182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T17:09:16Z","timestamp":1721063356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2019.1584182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,8]]},"references-count":227,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,5,24]]}},"alternative-id":["10.1080\/14656566.2019.1584182"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2019.1584182","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}